Heidi Health Raises $340M at $900M Valuation | AI Startup

Artificial intelligence is rapidly changing how healthcare professionals manage the demands of modern clinical practice, and Heidi Health is emerging as a notable company at the intersection of healthcare and AI. The Australian health AI startup has raised $340 million in new funding, including a $100 million Series C led by Blackbird and a separate $240 million growth investment from General Catalyst’s Customer Value Fund. The Series C values Heidi Health at $900 million, highlighting growing investor interest in AI-powered tools designed for healthcare professionals.

Founded in Melbourne, Heidi initially gained attention through its AI medical scribe, which helps clinicians capture consultations and generate clinical documentation. The company is now expanding its ambitions beyond documentation, positioning its technology as an AI Care Partner that supports broader clinical and administrative workflows under clinician supervision. Heidi says its platform currently supports around 2.8 million patient visits each week across 190 countries and 110 languages.

For readers of Technology Moment, Heidi Health’s latest funding round offers a useful look at where healthcare technology may be heading next. The story is not only about a major startup investment or a rising valuation; it also reflects the wider shift toward AI-assisted clinical workflows, medical documentation automation, and more specialized AI systems in healthcare. In this article, we explore Heidi Health’s funding, valuation, technology, investors, products, and its plans to take AI deeper into healthcare systems.

Heidi Health Raises $340 Million in New Funding

Australian health AI startup Heidi Health has raised $340 million in new funding, marking a significant expansion phase for the company as it develops AI-powered tools for healthcare professionals. The latest financing consists of a $100 million Series C funding round led by Blackbird, with participation from existing investors including Phoenix Court, Point72 Private Investments and Headline. Alongside the equity round, Heidi secured a separate $240 million growth investment from General Catalyst’s Customer Value Fund, bringing the total new funding to $340 million.

The funding gives Heidi Health additional resources to expand its healthcare AI platform across global health systems while continuing to develop clinical AI capabilities. The company says the capital will support deeper adoption within health systems, the development of agentic capabilities around patient visits, and the clinical safety, evidence, and regulatory infrastructure required for these technologies. This represents an important shift for an AI healthcare startup that initially became known for its AI medical scribe and clinical documentation tools.

Heidi Health has also grown its international footprint considerably. The company says its platform now supports approximately 2.8 million patient interactions each week across 190 countries and 110 languages. Its latest funding therefore arrives at a time when demand for healthcare technology, clinical workflow automation and medical AI is expanding across multiple markets. For Technology Moment readers, the announcement provides a useful example of how AI startup funding is moving beyond general-purpose applications toward specialized healthcare technology designed around specific clinical needs.

Heidi Health Valuation Reaches $900 Million

Following its latest $100 million Series C, Heidi Health reached a $900 million valuation, placing the Australian healthcare AI company among the increasingly prominent startups attracting substantial investment in medical AI. The valuation is associated with the Series C equity financing led by Blackbird, while the separate $240 million growth investment from General Catalyst brings the company’s total new financing package to $340 million. Keeping these two components separate is important because the $900 million valuation relates to the equity round rather than representing a valuation created by adding the two investments together.

The new valuation also reflects Heidi Health’s development since its earlier funding stages. According to recent reporting, the company raised a $65 million Series B in October 2025 at a $465 million valuation. The latest Series C therefore represents a substantial increase in the company’s reported valuation within roughly a year.

For the broader healthcare AI market, Heidi’s funding and valuation demonstrate the growing investor interest in specialized clinical AI rather than only consumer-facing artificial intelligence products. Heidi Health began with an AI medical scribe designed to help clinicians with documentation, but the company is now pursuing a much broader role across the healthcare workflow. Its platform includes documentation capabilities alongside products such as Heidi Evidence, Remote and Dictate, while its latest strategy focuses on supporting additional clinical and administrative tasks.

The $900 million valuation should therefore be viewed in the context of Heidi Health’s expansion from an AI healthcare startup focused primarily on medical documentation into a broader clinical AI technology company. Its progress illustrates how investors are placing increasing attention on AI systems that can be integrated into real-world healthcare environments.

What Is Heidi Health?

Heidi Health is an Australian healthcare technology company developing AI tools for clinicians and healthcare organizations. Founded in Melbourne, the company initially became known for its AI medical scribe, a technology designed to assist clinicians with clinical documentation during patient consultations. Rather than requiring doctors or other healthcare professionals to manually record every detail of an appointment, Heidi can transcribe consultations and use AI to generate structured clinical notes and other documents.

The company’s current vision extends beyond traditional medical transcription. Heidi describes itself as an AI Care Partner for clinicians, with the goal of supporting healthcare professionals across more parts of their working day. Its platform has expanded to include products such as Heidi Evidence, which provides clinical evidence and research at the point of care, Remote, a hardware device designed for audio capture, and Dictate, a voice-to-text feature. The scale of Heidi Health has also grown rapidly. The company reports that its AI Care Partner supports around 2.8 million patient interactions each week across 190 countries and 110 languages. It has also reported more than 175 million patient visits and over 67 million clinical hours supported since launch.

At its core, Heidi Health focuses on using artificial intelligence in healthcare to reduce administrative work and give clinicians more time to concentrate on patients. Its technology combines clinical documentation, medical AI software, and workflow assistance rather than functioning simply as a general-purpose chatbot. This specialized approach is particularly relevant to the wider development of clinical AI, where accuracy, privacy, safety, and integration with existing healthcare systems are important considerations. The company’s latest funding signals its intention to take this approach further by expanding from documentation into broader supervised healthcare workflows.

How Heidi Health Uses AI in Healthcare

Heidi Health uses AI to address one of the practical challenges faced by healthcare professionals: the amount of documentation and administrative work surrounding patient care. Its best-known application is an AI medical scribe that can transcribe clinical consultations and generate structured notes. According to Heidi’s help documentation, clinicians can use the platform to create notes from consultations, personalize templates,s and generate additional documents such as referral letters and patient summaries.

This makes Heidi an example of clinical documentation AI rather than a general-purpose AI assistant. The technology is designed around healthcare workflows, where information from a patient interaction can be converted into documentation that clinicians can review and edit. The company also offers Dictate for voice-to-text tasks and Heidi Evidence for accessing clinical research and guidance at the point of care.

The broader objective is healthcare automation. Instead of limiting AI to transcription, Heidi is developing capabilities that can support tasks around the patient visit. The company has described areas such as pre-charting, diagnostic follow-up, and other operational work as part of its move toward broader clinical workflow automation. Importantly, Heidi says its approach keeps medical judgment with the human clinician, positioning AI as an assistant rather than an independent replacement for healthcare professionals.

Heidi also says it invested early in purpose-built medical foundation models rather than relying entirely on general-purpose AI systems. The company states that its transcription and note-generation workloads run largely on technology developed in-house, allowing it to optimize accuracy, speed, and cost for particular clinical tasks. As a result, Heidi Health’s approach combines AI-powered healthcare, medical documentation automation, clinical workflow automation, and clinical AI technology. The company’s latest funding is intended to extend these capabilities into additional healthcare workflows while maintaining clinical safety and human oversight.

From AI Medical Scribe to Agentic AI

Heidi Health’s latest strategy represents a shift from being primarily an AI medical scribe to becoming a broader AI Care Partner for clinicians. The original scribe model focused on an important but relatively defined task: capturing the clinical conversation and turning it into useful documentation. Heidi says its next stage is about going beyond the completed note and helping clinicians handle some of the work that follows or surrounds a patient visit.

This is where the concept of agentic AI in healthcare becomes relevant. Instead of simply responding to a prompt or producing a document, an AI agent can be designed to work through multiple steps of a defined workflow and return information or completed tasks for human review. Heidi has described potential areas including pre-charting, following up on diagnostics,s and other operational activities. The company’s stated approach is that medical judgment remains with the clinician, while AI can take on appropriate administrative or workflow tasks under supervision.

The distinction is important because healthcare environments require more than technically capable AI. Clinical systems must also address accuracy, safety, evidence, privacy, and regulatory requirements. Heidi says part of its new investment will support clinical evidence, quality management systems, and regulatory work associated with its agentic AI development.

Heidi’s existing products provide a foundation for this transition. Its AI scribe handles documentation, Heidi Evidence brings clinical research into the workflow, Remote supports audio capture, and Dictate provides voice-to-text functionality. Together, these capabilities give the company a broader healthcare workflow platform rather than a single-purpose transcription tool.

The move from AI medical scribe to agentic AI therefore represents a change in how healthcare AI can be applied. The focus is shifting from simply recording what happened during a consultation toward helping clinicians manage parts of the wider clinical workflow. For Heidi Health, the latest $340 million funding provides capital to develop this vision while keeping clinicians responsible for medical decisions.

What Does Heidi Health Do?

Heidi Health is an Australian health AI startup that develops software designed to help clinicians manage documentation, clinical information,n and other parts of the healthcare workflow. Founded in Melbourne, the company initially became known for its AI medical scribe, which can capture conversations between clinicians and patients and turn them into structured clinical notes and other follow-up materials. Rather than functioning as a general-purpose AI chatbot, Heidi focuses its technology on specific healthcare tasks where documentation and administrative work can consume significant amounts of a clinician’s time.

The company’s broader goal is now to build an AI Care Partner that can support clinicians throughout the working day. Heidi says its platform has supported more than 175 million patient visits and over 67 million clinical hours, with users across 190 countries and 110 languages. Its technology is also being integrated into major healthcare environments, including public and private health systems in the United States, United Kingdom, Australia, New Zealand and Canada.

At the product level, Heidi combines several areas of medical AI software. Its AI scribe focuses on clinical documentation, while Heidi Evidence provides clinical information at the point of care. The company has also introduced Remote, a wearable hardware device designed for audio capture, and Dictate, a voice-to-text feature. Together, these products are intended to connect documentation, clinical knowledge,ge and workflow support within one healthcare technology platform.

Heidi’s latest strategy goes beyond simply helping doctors write notes. The company says it wants AI to assist with work surrounding patient visits, including administrative and clinical workflows, while keeping medical judgment with the human clinician. This places Heidi Health within the wider AI healthcare, clinical AI, and healthcare automation market, where specialized technology is increasingly being developed to support healthcare professionals rather than replace them.

Heidi Health’s AI Products and Features

Heidi Health has developed a growing collection of AI-powered healthcare products aimed at different parts of clinical practice. Its best-known offering is its AI medical scribe, which helps clinicians capture patient conversations and generate clinical documentation. The company describes this as the foundation of its AI Care Partner platform, allowing clinicians to spend less time manually preparing notes and more time interacting with patients. Heidi’s AI scribe can work with clinical encounters and clinician dictation, producing notes, summaries, and other follow-up materials.

Another part of the platform is Heidi Evidence, which brings clinical guidelines and medical research into the point-of-care workflow. According to Heidi, Evidence has answered more than 10 million queries since launching in March 2026. The product is intended to help clinicians access relevant medical information without leaving their existing workflow, making it an example of how clinical AI technology can combine documentation with access to clinical knowledge.

Heidi has also introduced Remote, a wearable device designed for reliable audio capture across different healthcare settings, and Dictate, a voice-to-text feature for clinicians. These products expand Heidi beyond traditional medical transcription and give the company additional ways to capture information during clinical work. The company is also developing deeper connections with electronic health record systems. Heidi has previously expanded its Epic integration to mobile through Epic’s Haiku application, giving clinicians access to its AI care platform within an existing clinical environment.

Together, these features show Heidi’s broader approach to clinical workflow automation. Instead of treating AI medical documentation as a standalone tool, the company is building a connected platform covering documentation, medical evidence, voice capture,e and workflow assistance. Its latest strategy is to extend these capabilities toward supervised AI agents that can handle additional tasks around patient visits while leaving medical decisions with clinicians.

Who Invested in Heidi Health?

Heidi Health has attracted investment from a group of global technology and venture investors as the company has expanded its healthcare AI platform. Its latest financing, announced in September 2026, consists of two separate components: a $100 million Series C equity round led by Blackbird and a $240 million growth investment led by General Catalyst’s Customer Value Fund. Together, these transactions bring Heidi’s new funding to $340 million, while the Series C values the company at $900 million.

Blackbird has been an important investor in Heidi’s development and led the latest Series C. Existing investors participating in that round include Phoenix Court, Point72 Private Investments and Headline. Heidi has previously received backing from several other investors, including Possible Ventures, Glitch Capital and Archangel. The company says its total capital raised has reached $436.6 million following the latest financing.

General Catalyst is also playing a significant role in Heidi’s latest growth phase. Its Customer Value Fund provided the separate $240 million growth investment. Unlike a conventional equity investment, this type of financing is designed to provide growth capital while using the company’s future revenue from new customers to support the investment structure. MobiHealthNews describes the arrangement as nondilutive growth financing, meaning it does not work in the same way as selling additional company equity.

Heidi’s earlier funding history also shows the company’s rapid development. In October 2025, it closed a $65 million Series B at a reported $465 million valuation. Before that, the company raised additional Series A funding, including a $17 million round in March 2025. The investor interest reflects Heidi’s expansion from an AI medical scribe into a broader clinical AI platform. Its investors are backing a company that is now targeting healthcare documentation, clinical knowledge, workflow automation,n and eventually more supervised AI capabilities across health systems.

Why Is Heidi Health Raising So Much Capital?

Heidi Health says its latest $340 million funding will support the next phase of its expansion across global healthcare systems. The company is moving beyond its original focus on clinical documentation and wants to develop AI capabilities that can support more of the work surrounding patient visits. According to Heidi, the investment will help deepen adoption within health systems, develop agentic capabilities,es and strengthen the clinical safety, regulatory, and evidence foundations required for these technologies.

One major reason for the investment is Heidi’s ambition to expand its AI Care Partner model. The company says healthcare professionals still spend considerable time on tasks that happen before and after a consultation, including administrative work, pre-charting and following up on diagnostics. Heidi wants its technology to move beyond generating a clinical note and eventually assist with parts of these broader workflows. The company emphasizes that medical judgment remains with clinicians.

The funding will also support expansion within large health systems. Heidi reports an enterprise activation rate of around 62% and says its technology has been adopted by organizations including Beth Israel Lahey Health in the United States, NHS England Midlands in the UK, and healthcare organizations in Australia and New Zealand.

Another important area is the development of agentic AI healthcare technology. Heidi says its next-generation capabilities will require additional clinical evidence, quality-management systems and regulatory submissions. This means the company is investing not only in software development but also in the infrastructure needed to deploy clinical AI responsibly. The company’s financial growth also helps explain the scale of the latest investment. Heidi says its annual recurring revenue increased from $1 million to $50 million in two years, while its platform now supports around 2.8 million patient interactions every week.

Why Healthcare AI Is Attracting More Investment

Healthcare AI is attracting increasing investment because artificial intelligence is moving from experimental technology into practical healthcare workflows. Investors are increasingly interested in companies that can solve specific problems for clinicians, particularly documentation, administrative workload, clinical information access, and workflow automation. Heidi Health is an example of this trend, with its latest financing combining a $100 million Series C and a separate $240 million growth investment, bringing total new funding to $340 million.

One important area is the growth of AI medical scribe technology. Clinicians spend significant time creating notes, reviewing information, and completing administrative tasks around patient consultations. AI-powered documentation tools can assist with these repetitive activities, potentially allowing healthcare professionals to devote more time to patient-facing work. Heidi has built its platform around this opportunity and is now expanding beyond documentation into broader clinical workflows.

The investment environment also reflects a wider interest in healthcare AI, clinical AI,I and healthtech investment. A Silicon Valley Bank report found that nearly $18 billion of US and European venture capital investment went into healthcare AI in 2025, with AI representing 46% of healthcare investment in its analysis. The report also highlighted growing investment in large AI deals, including technologies such as ambient documentation.

Another factor is the development of agentic AI healthcare. Instead of simply generating information, newer AI systems are being designed to assist with multi-step workflows. Heidi says its future platform will move from documentation toward supervised action, with clinicians retaining control over medical decisions. For investors, this creates a broader opportunity around AI healthcare startups that can integrate deeply into real clinical environments rather than offering generic AI software.

Heidi Health Funding: Key Numbers at a Glance

Heidi Health’s latest financing represents one of the significant funding events in the current healthcare AI market. The company announced $340 million in new funding on September 22, 2026. Importantly, this figure combines two different financing arrangements rather than representing a single $340 million equity round. The first is a $100 million Series C equity financing led by Blackbird, while the second is a $240 million growth investment led by General Catalyst’s Customer Value Fund.

The Series C places Heidi Health at a $900 million valuation, according to the company. The round included participation from existing investors Phoenix Court, Point72 Private Investments and Headline. The separate General Catalyst investment is designed to provide additional growth and go-to-market capacity. The latest announcement brings Heidi’s reported total capital raised to approximately $436.6 million, according to the company. Heidi was founded in Melbourne, Australia, and has grown from an AI medical scribe startup into a broader clinical AI platform.

Heidi also reports strong operational growth. Its platform has supported more than 175 million patient visits and over 67 million clinical hours, while annual recurring revenue grew from $1 million to $50 million in two years. These figures help explain why Heidi Health has attracted substantial healthtech investment. The company is combining an established AI medical documentation product with a broader strategy around healthcare automation, clinical workflow, and supervised agentic AI.

Frequently Asked Questions About Heidi Health

How much funding did Heidi Health raise?

Heidi Health raised $340 million in new funding in September 2026. The financing consists of a $100 million Series C equity round led by Blackbird and a separate $240 million growth investment from General Catalyst’s Customer Value Fund, according to Heidi Health’s announcement.

What is Heidi Health’s valuation?

Heidi Health reached a $900 million valuation following its $100 million Series C funding round. The Series C was led by Blackbird, with participation from existing investors. The separate $240 million General Catalyst growth investment brings the total new capital announced in the financing package to $340 million.

Who invested in Heidi Health?

The latest Series C was led by Blackbird, with Phoenix Court, Point72 Private Investments and Headline also participating. Separately, General Catalyst’s Customer Value Fund provided a $240 million growth investment. Heidi has also received backing from several investors during earlier funding rounds as its healthcare AI platform expanded.

What does Heidi Health do?

Heidi Health develops AI healthcare software designed to help clinicians with documentation and workflow-related tasks. Its platform includes an AI medical scribe, clinical evidence capabilities, voice-to-text functionality,y and Remote audio-capture technology. The company is also developing broader AI Care Partner capabilities for supervised clinical and administrative workflows.

What is Heidi Health AI Scribe?

Heidi Health AI Scribe is an AI medical documentation tool that can process clinical conversations or clinician dictation and help generate structured notes and other documents. The technology is designed to reduce repetitive documentation work, while clinicians can review, edit, and finalize the generated content before using it.

Why did Heidi Health raise $340 million?

Heidi Health says the new funding will support global health-system expansion, development of supervised AI capabilities,s and continued investment in clinical safety, evidence,ce and regulatory infrastructure. The company is moving beyond documentation toward broader healthcare workflow automation, while maintaining clinician oversight of medical decisions.

What is an AI medical scribe?

An AI medical scribe is software that uses artificial intelligence to assist healthcare professionals with clinical documentation. It can process information from patient consultations or dictation and generate draft clinical notes or related documents. Clinicians can then review and modify the generated material before incorporating it into patient records.